Piramal Pharma Solutions has made a multimillion dollar investment to create a world-class high-throughput screening facility that will augment the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India.
This new expansion, which is expected to go live in Q3 2022, will significantly add to the primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.
The CDMO says that by offering integrated chemistry and biology services from a single site, customers can anticipate significant improvements to drug discovery cycle times.
The new high-throughput screening technology enables Piramal Pharma Solutions to evaluate and screen 1000 compounds per week using various assay platform technologies such as fluorescent imaging plate reader (FLIPR), time-resolved fluorescence resonance energy transfer/homogeneous time-resolved fluorescence (TR-FRET/HTRF), fluorescence polarisation (FP), absorbance, luminescence/electrochemiluminescence (ECL), alpha screen, lantha screen, flow cytometry, and high content imaging. These platforms will be applicable to a variety of targets including, for example, G-protein-coupled receptors (GPCRs) and kinase-targeted therapies.
In addition, new personnel with experience in biology services are being added to the site team, complementing the existing technical and operational expertise.